OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Kunz on the Importance of Tailoring Treatments to Patients With NETs

November 18th 2021

Pamela Kunz, MD, discusses the importance of tailoring treatments to individual patients with neuroendocrine tumors.

Dr. Toppmeyer on the Utility of De-Escalation Trials in HER2+ Breast Cancer

November 18th 2021

Deborah L. Toppmeyer, MD, discusses the utility of clinical trials evaluating de-escalated treatment approaches in HER2-positive breast cancer.

Dr. Ghodoussipour on Ongoing Trials in Non–Muscle Invasive Bladder Cancer

November 18th 2021

Saum Ghodoussipour, MD, discusses ongoing trials in non–muscle invasive bladder cancer.

Dr. Toomey on the Importance of De-Escalation Clinical Trials in HER2+ Breast Cancer

November 18th 2021

Kathleen C. Toomey, medical oncologist, discusses the importance of clinical trials evaluating de-escalated treatment strategies in HER2-positive breast cancer.

Dr. Shah on Trials Examining Cilta-Cel in Relapsed/Refractory Multiple Myeloma

November 18th 2021

Mansi R. Shah, MD, discusses ongoing research examining the CAR T-cell therapy ciltacabtagene autoleucel for the treatment of patients with relapsed or refractory multiple myeloma.

Dr. Cooper on Leveraging Novel Agents and Combos in Multiple Myeloma

November 18th 2021

Dennis Cooper, MD, sheds light on the novel therapeutic regimens available to patients with multiple myeloma.

Dr. Li on the Interim Results of a Phase 1 Trial With Surufatinib in NETs

November 17th 2021

Daneng Li, MD, discusses the interim analysis results of a phase 1 trial evaluating surufatinib in United States patients with neuroendocrine tumors.

Dr. Reidy-Lagunes on the Results of the SPINET Study by Tumor Subtype in BP-NETs

November 17th 2021

Diane Reidy-Lagunes, MD, discusses the results of the phase 3 SPINET trial by tumor subtype in bronchopulmonary neuroendocrine tumors.

Dr. Kimmick on the Evolving HER2+ Breast Cancer Treatment Paradigm

November 16th 2021

Gretchen G. Kimmick, MD, MS, discusses the quickly evolving treatment paradigm for patients with HER2-positive breast cancer.

Dr. Raj on Injection Site Pain With Octreotide Long-Acting Release Vs Lanreotide in NETs

November 16th 2021

Nitya Raj, MD, discusses the results of a phase 4 trial comparing injection site pain with octreotide long-acting release vs lanreotide in well-differentiated neuroendocrine tumors.

Dr. Halperin on the Efficacy of the Protocol PEN-221-001 Study in Advanced GI NETs

November 16th 2021

Daniel M. Halperin, MD, discusses the efficacy and safety results of the phase 1/2a Protocol PEN-221-001 trial in advanced gastrointestinal mid-gut neuroendocrine tumors.

Dr. Bupathi on First-Line Treatment Options for Clear Cell RCC

November 16th 2021

Manojkumar Bupathi, MD, MS, discusses the improvement in first-line treatment options for patients with clear cell renal cell carcinoma.

Dr. Ciombor on Anti-EGFR Therapy in Metastatic CRC

November 16th 2021

Kristen K. Ciombor, MD, MSCI, discusses the use of anti-EGFR therapy for the frontline treatment of patients with metastatic colorectal cancer.

Dr. Stephens on Early Intervention With Targeted Agents in CLL

November 15th 2021

Deborah M. Stephens, DO, discusses early intervention with targeted agents to improve outcomes in patients with high-risk chronic lymphocytic leukemia.

Dr. Langer on the Evolution of Molecular Testing in Advanced NSCLC

November 15th 2021

Corey J. Langer, MD, professor of medicine, University of Pennsylvania, director, Thoracic Oncology, Penn Medicine, discusses the evolution of molecular testing in advanced non–small cell lung cancer.

Dr. Le on the Emergence of Antibody-Drug Conjugates in NSCLC

November 15th 2021

Xiuning Le, MD, PhD, discusses the emergence of antibody-drug conjugates in non–small cell lung cancer.

Dr. Patel Discusses Novel Targets in NSCLC

November 15th 2021

Sandip P. Patel, MD, discusses novel targets in non–small cell lung cancer.

Dr. Martin on the Utility of CAR T-Cell Therapy in Late Relapsed Multiple Myeloma

November 12th 2021

Thomas G. Martin, MD, discusses the utility of CAR T-cell therapy in late relapsed multiple myeloma.

Dr. Mikhael on the Promise of Bispecific Antibodies in Multiple Myeloma

November 12th 2021

Joseph Mikhael, MD, discusses the promise of bispecific antibodies in multiple myeloma.

Dr. Lentzsch on How Patient Age Informs Treatment Decisions in Multiple Myeloma

November 12th 2021

Suzanne Lentzsch, MD, discusses how patient age informs treatment decisions in multiple myeloma.